



## Short Communication

## Mutation c.359\_363delGTATTinsATAC in the COL4A5 Causes alport syndrome in a Chinese family

Qiufen Wang<sup>a,b,1</sup>, Fei Liu<sup>a,1</sup>, Yue Xing<sup>a</sup>, Xianjin Wei<sup>c</sup>, Hui Li<sup>a</sup>, Shirong Zhang<sup>a</sup>, Jingyu Liu<sup>a</sup>, Qing Wang<sup>a</sup>, Zhaohui Tang<sup>a,\*</sup>, Mugen Liu<sup>a</sup>

<sup>a</sup> Key Laboratory of Molecular Biophysics of Ministry of Education, College of Life Science and Technology, Center for Human Genome Research, Huazhong University of Science and Technology, Wuhan, Hubei 430074, China

<sup>b</sup> Union Hospital, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China

<sup>c</sup> The Pinghu Traditional Chinese Medicine Hospital, Pinghu, Zhejiang, 314200, China

## ARTICLE INFO

## Article history:

Accepted 10 October 2012

Available online 18 October 2012

## Keywords:

Type IV collagen

Renal disease

Linkage

Frameshift mutation

Phenotype

## ABSTRACT

The X-linked form of Alport syndrome is associated with mutations in the *COL4A5* gene, which is located at Xq22.3 and encodes the  $\alpha 5$  chain of type IV collagen. Here we clinically characterized a Chinese family with Alport Syndrome, but no ocular or hearing abnormalities have been observed in any patient in the family. Through Linkage analysis and direct DNA sequencing, a novel complex deletion/insertion mutation c.359\_363delGTATTinsATAC in the *COL4A5* gene was identified in the family. The mutation was found in all affected family members, but was not present in the unaffected family individuals or the 200 controls. The predicted mutant protein in the family is a truncated protein consisting of only 153 residues. Our report for the first time revealed that the frameshift mutation in the type IV collagen chain  $\alpha 5$  causes only renal disease, without extrarenal lesion. Our study broadens genotypic and phenotypic spectrum of *COL4A5* mutations associated with Alport syndrome.

© 2012 Elsevier B.V. All rights reserved.

## 1. Introduction

Alport syndrome (MIM #301050, AS) is a hereditary disorder of the basement membrane, resulting in progressive renal failure due to glomerulonephropathy, variable sensorineural hearing loss, and ocular anomalies (Gross et al., 2002). The pathogenesis of AS is related to the defect in the *COL4A3*, *COL4A4* and *COL4A5* genes encoding type IV collagen  $\alpha$ -chain isoforms ( $\alpha 3$ ,  $\alpha 4$ , and  $\alpha 5$ ). These three genes are necessary for proper development of the glomerular basement membranes, which plays a crucial role in the purification of blood plasma in the kidney (Kalluri et al., 1997). AS is a genetically heterogeneous disease. About 85% of AS patients have X-linked AS (XLAS), caused by mutations in the *COL4A5* gene, which is located on chromosome X (Barker et al., 1990; Gross et al., 2002). *COL4A3* and *COL4A4* genes, located on chromosome 2, are involved in approximately 15% of autosomal recessive AS cases and the rarer autosomal

dominant forms of AS (Jefferson et al., 1997; Mochizuki et al., 1994; van der Loop et al., 2000). XLAS males have severer phenotypes and usually progress to end-stage renal disease (ESRD), whereas the affected females, heterozygous for the *COL4A5* mutant gene, have more variable phenotypes, from microscopic hematuria to ESRD (Kashtan, 2000).

To date, 688 *COL4A5* mutations have been identified according to the Human Gene Mutation Database (HGMD Professional 2012.1. Release date 30th March 2012) (<http://www.hgmd.org/>). Certain correlations between genotypes and phenotypes have been established in males (Bekheirnia et al., 2010; Gross et al., 2002; Jais et al., 2000). Patients with large deletions, nonsense or frameshift mutations demonstrated severer symptoms as compared to those with missense or splice site mutations. However, such genotype–phenotype correlations have not been found in females with variable phenotypes, even among family members (Jais et al., 2003).

In this study, we looked into a Chinese family with AS. Clinical examinations revealed that all affected members in the family displayed renal disorders, but no sensorineural hearing loss or variable ocular anomalies were found. Through genetic study, we identified a novel complex deletion/insertion mutation c.359\_363delGTATTinsATAC in the *COL4A5* gene in the AS family. The effect of this mutation is the production of a truncated protein of 153 residues. Our data broaden the genotypic spectrum of *COL4A5* mutations associated with mild Alport syndrome.

**Abbreviations:** *COL4A5*, the  $\alpha 5$  chain of type IV collagen; AS, Alport syndrome; XLAS, X-linked Alport syndrome; *COL4A3*, the  $\alpha 3$  chain of type IV collagen; *COL4A4*, the  $\alpha 4$  chain of type IV collagen; ESRD, end-stage renal disease; HGMD, the Human Gene Mutation Database; NC I, non-collagenous domain I.

\* Corresponding author at: Center for Human Genome Research, Huazhong University of Science and Technology, Wuhan, Hubei 430074, China. Tel.: +86 27 87792649; fax: +86 27 87794549.

E-mail address: [zh\\_tang@mail.hust.edu.cn](mailto:zh_tang@mail.hust.edu.cn) (Z. Tang).

<sup>1</sup> Qiufen Wang and Fei Liu contributed equally to this work.

**2. Materials and methods**

**2.1. Study subjects**

A Chinese family with multiple individuals affected with Alport syndrome was enrolled in this study. They are from Zhejiang province of the People's Republic of China. Clinical diagnosis was performed for the participants, including a comprehensive review by a consultant ophthalmologist and an ENT surgeon. Ocular examination included visual acuity and examination for anterior lenticonus, cataract, or optic disc or retinal abnormalities. Examinations for sensorineural hearing loss were carried out using standard audiometry tests. Informed consent was obtained from the participants in accordance with the study protocols approved by the Ethics Committee of Huazhong University of Science and Technology.

**2.2. Haplotype analysis**

Genomic DNA was extracted from peripheral whole blood samples using Wizard Genomic DNA Purification Kit (Promega, Madison, WI). Four polymorphic microsatellite markers close to COL4A5 (MIM \*303630), including DXS8084, DXS6797, DXS1059, and DXS1220 (Applied Biosystems, Inc., Foster City, CA), were selected to investigate if the main X-linked COL4A5 gene may be the disease-causing gene in this family.

**2.3. Mutational analysis**

The proband DNA sample was used for initial mutational analysis. All exons and intron–exon junctions of COL4A5 (Genbank No:NM\_000495) were amplified by PCR and mutational analysis was carried out using direct DNA sequence analysis with primers described previously (Tang et al., 2008). PCR products were run on a 1.5% agarose gel, purified using the QIAquick Gel Extraction Kit (Qiagen Inc., Valencia, CA), and sequenced with both forward and reverse primers. DNA sequencing was carried out using the BigDye Terminator Cycle Sequencing v3.1 kit (ABI, Foster City, CA). To determine whether the mutation co-segregated with the disease in the family and whether the mutation was absent in 200 normal controls, the exon 6 of COL4A5 in all family members and the 200 controls were amplified by PCR and sequenced with both forward and reverse primers.

**Table 1**

The clinical manifestation of patients in the family with mutations in COL4A5. \*The data are according to the clinical documents of these three patients before they died.

ID	Gender	Age of ESRD	Haematuria	Eyes lesions	Hearing loss
I2*	F	54	+	–	–
II2*	M	30	+	–	–
II4	F	–	+	–	–
II6*	F	42	+	–	–
II8	F	–	+	–	–
III1	F	–	+	–	–
III3	F	–	+	–	–

**3. Results**

**3.1. Pedigree analysis**


The pedigree consists of three generations including 18 members (8 males and 10 females) (Fig. 1). The proband (III 1), the cousin (III 3), and two paternal aunts (II 4,II 8) have mild hematuria. The father (II 2), the paternal grandmother(I 2), and one of her paternal aunt (II 6) of the proband reached the ESRD stage at 30, 54 and 42 year-old respectively, and they all died of ESRD. No ocular or hearing abnormalities have been observed in any member of the family (Table 1 and Fig. 1).

**3.1.1. Haplotype analysis**


Haplotype analysis revealed the same haplotype in all affected family members. This result suggests that the disease-causing gene in the family may be the COL4A5 gene (Fig. 1).

**3.2. Mutation analysis**

To identify the causative mutation in the family, we sequenced the entire coding region and exon–intron boundaries of the COL4A5 gene. A complex deletion/insertion mutation (c.359\_363delGTATTinsATAC) in exon 6 was identified in the proband (Fig. 2). It resulted in a frameshift in codon 120 and produced a truncated protein with only 153 amino acids including an aberrant 33 residues. Direct DNA sequence analysis of the members of the family showed that the mutation co-segregated with disease, and was not present in unaffected family members or 200 normal control individuals. This suggests that this



**Fig. 1.** Pedigree structure of the Chinese Alport syndrome family and results from Haplotype analysis for markers on chromosome Xq23. Blackened and open bars indicate disease and normal haplotypes, respectively. Filled squares or filled circles represent individuals affected with AS. Normal individuals are shown with empty squares (males) and circles (females). Haplotype analysis showed that all patients in the family inherited affected alleles from I2, whereas all unaffected members inherited alleles contain normal COL4A5.



**Fig. 2.** Identification of the complex mutation in the studied family. A. Shows exon 6 sequences from a normal individual. B. Indicates the mutated allele with the complex c.359–363delGTATTinsATAC. C. The sequence of a female affected individual with heterozygous mutation c.359–363delGTATTinsATAC. D. c.359–363delGTATTinsATAC causes frameshift and substitutes amino acids 120–153 by abnormal residues, and results in a truncated *COL4A5* protein with only 153 amino acid residues.

novel mutation of *COL4A5* is not rare polymorphisms, but a disease-causing mutation for Alport syndrome in the pedigree.

#### 4. Discussion

In this study, we investigated a Chinese Alport syndrome family. Through linkage analysis and direct DNA sequencing, we identified a novel deletion/insertion mutation c.359\_363delGTATTinsATAC in the *COL4A5* gene. This mutation caused a change in the reading frame and introduced a premature *COL4A5* short of NC I domain, containing only 153 amino acids with an aberrant 33 residues. However, it is probable that the frameshift mutation may cause nonsense mediated mRNA-decay, it may cause rapid degradation mRNA and lead to no mutant *COL4A5* protein in patients of this family.

X-linked AS is phenotypically heterogeneous with a wide variability in the rate of progression to end-stage renal disease, the type of glomerular basement membrane abnormalities, and the association with extrarenal symptoms such as deafness and ocular lesion (Jais et al., 2003). The relationship between disease manifestations in females with *COL4A5* mutations and X-inactivation have been reported (Demosthenous et al., 2012; Kashtan, 2009; Migeon, 2008; Wang et al., 2007). Statistical analyses of the genotype–phenotype relations based on a large number of clinical materials have shown that mutations which were predicted to result in the complete absence of  $\alpha 5$  (IV) chains or truncated  $\alpha 5$  (IV) chains without non-collagenous (NC I) domain consistently cause the juvenile form of AS, whose renal failure generally appears in the early twenties with significant extrarenal lesion (Gross et al., 2002; Jais et al., 2000). However, the patients with the mutation in *COL4A5* as we reported here displayed variable phenotypes. The renal phenotypes were less severe and onset later, although this mutation results in truncated  $\alpha 5$  (IV) chains without NC I domain.

Moreover, all patients of the pedigree only have renal symptom without extrarenal defect as shown in Table 1, which was similar to the clinical symptoms reported by Wilson et al., who identified a mutation in the NC I domain of *COL4A5* which causes a late onset renal failure without extra-renal abnormalities. The difference is that the

mutation they found is a missense mutation (Wilson et al., 2007), while the one we found indicates that a frameshift mutation in *COL4A5* might also cause atypical Alport Syndrome.

The only male patient (II 2) in this family progressed to ESRD at 30 years old, much earlier than his mother at 54 years, and also did not exhibit hearing loss and ophthalmological changes. According to Jais et al.'s study (Jais et al., 2000), the probability of developing ESRD before the age of 30 years in patients with frameshift mutations was found to be 90%. It is interesting that the phenotypic features observed in the AS family were different from most of mutation carriers of *COL4A5*. The precise molecular mechanisms of these mutant proteins causing AS will be further studied.

#### Acknowledgments

We are grateful to the XLAS family for their participation in this study. This study was supported by grants from Chinese National Natural Science Foundation grant nos. 30771199, 30871386, and 31071106.

#### References

- Barker, D.F., et al., 1990. Identification of mutations in the *COL4A5* collagen gene in Alport syndrome. *Science* 248, 1224–1227.
- Bekheirnia, M.R., et al., 2010. Genotype–phenotype correlation in X-linked Alport syndrome. *J. Am. Soc. Nephrol.* 21, 876–883.
- Demosthenous, P., et al., 2012. X-linked Alport syndrome in Hellenic families: phenotypic heterogeneity and mutations near interruptions of the collagen domain in *COL4A5*. *Clin. Genet.* 81, 240–248.
- Gross, O., Netzer, K.O., Lambrecht, R., Seibold, S., Weber, M., 2002. Meta-analysis of genotype–phenotype correlation in X-linked Alport syndrome: impact on clinical counselling. *Nephrol. Dial. Transplant.* 17, 1218–1227.
- Jais, J.P., et al., 2000. X-linked Alport syndrome: natural history in 195 families and genotype–phenotype correlations in males. *J. Am. Soc. Nephrol.* 11, 649–657.
- Jais, J.P., et al., 2003. X-linked Alport syndrome: natural history and genotype–phenotype correlations in girls and women belonging to 195 families: a “European Community Alport Syndrome Concerted Action” study. *J. Am. Soc. Nephrol.* 14, 2603–2610.
- Jefferson, J.A., et al., 1997. Autosomal dominant Alport syndrome linked to the type IV collagen alpha 3 and alpha 4 genes (*COL4A3* and *COL4A4*). *Nephrol. Dial. Transplant.* 12, 1595–1599.
- Kalluri, R., Shield, C.F., Todd, P., Hudson, B.G., Neilson, E.G., 1997. Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading

- to increased susceptibility of renal basement membranes to endoproteolysis. *J. Clin. Invest.* 99, 2470–2478.
- Kashtan, C.E., 2000. Alport syndromes: phenotypic heterogeneity of progressive hereditary nephritis. *Pediatr. Nephrol.* 14, 502–512.
- Kashtan, C.E., 2009. Women with Alport syndrome: risks and rewards of kidney donation. *Nephrol. Dial. Transplant.* 24, 1369–1370.
- Migeon, B.R., 2008. X inactivation, female mosaicism, and sex differences in renal diseases. *J. Am. Soc. Nephrol.* 19, 2052–2059.
- Mochizuki, T., et al., 1994. Identification of mutations in the alpha 3(IV) and alpha 4(IV) collagen genes in autosomal recessive Alport syndrome. *Nat. Genet.* 8, 77–81.
- Tang, Z., et al., 2008. A novel COL4A5 splicing mutation causing Alport syndrome in a Chinese family. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi* 25, 649–652.
- van der Loop, F.T., et al., 2000. Autosomal dominant Alport syndrome caused by a COL4A3 splice site mutation. *Kidney Int.* 58, 1870–1875.
- Wang, Y., Zhang, H., Ding, J., Wang, F., 2007. Correlation between mRNA expression level of the mutant COL4A5 gene and phenotypes of XLAS females. *Exp. Biol. Med. (Maywood)* 232, 638–642.
- Wilson, J.C., Yoon, H.S., Walker, R.J., Eccles, M.R., 2007. A novel Cys1638Tyr NC1 domain substitution in alpha5(IV) collagen causes Alport syndrome with late onset renal failure without hearing loss or eye abnormalities. *Nephrol. Dial. Transplant.* 22, 1338–1346.